Innovation in targeted protein degradation—driven by PROTACs (PROteolysis-TArgeting Chimeras) and molecular glues—is accelerating. These small-molecule drugs work by removing unwanted proteins from a cell rather than simply blocking their activity.
This approach enables access to targets once considered undruggable and offers the potential for improved safety and more precise dosing. Leveraging their catalytic mechanism of action, researchers are advancing new therapeutic options for a broad range of targets, spanning cancer to neurodegenerative diseases.
This eBook examines how PROTACs and other degraders are advancing drug development. Focusing on microplate-based assays, it outlines options for streamlining discovery and development for this class of molecules, including assay types suited to different stages of the protein degradation pathway and detection methods proven effective in research and development.
Download your copy now to read on!
About BMG LABTECH GmbH
BMG LABTECH has been committed to producing microplate readers for more than twenty years. By focusing on the needs of the scientific community, the company’s innovative microplate readers have earned the company the reputation of being a technology leader in the field.
BMG LABTECH has developed a wide range of dedicated and multi-mode microplate readers for life sciences applications and high-throughput screening.
All BMG LABTECH microplate readers are "Made in Germany" and are conceived, developed, assembled, and tested entirely at our headquarters in Germany.
Since our establishment in Offenburg, Germany in 1989, BMG LABTECH has expanded to offer a worldwide sales and support network with offices in the USA, UK, Australia, Japan and France. Our subsidiaries, regional offices and distributors are committed to bringing you innovative microplate reader technology with the quality and reliability you expect from a German company.
Our staff includes engineers and scientists from the fields of biology, biochemistry, analytical chemistry, and physics.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.